Ann: Trading Halt, page-42

I suspect they are waiting until after it is all approved before starting marketing. There are potentially a whole bunch of announcements which they can make which can drive a marketing campaign - patent approvals, ethics approvals, new clinical sites, first patient dosed in phase 2, orphan designation, research agreements, etc.
Given the solid buying support at 1c over the last few weeks I am sure the days of sub 1c are over. The dust is settling and sellers are reducing. Soon the company will be recognised for what it is - a phase 2 biotech targeting a large market, generating some revenue (check last year's prospectus), with $3.5m cash and a low market cap of about $15m.